Adjunto referencia del Congreso de Oncología Radioterápica de La Rioja que se celebrará los días 22 y 23 de éste mes de mayo. En el mismo se reunirán especialistas tanto nacionales como internacionales en Medicina Nuclear, Radiofisica, Radioterapia, Radiofarmacia, Radiologia y Oncologia Medica entre otras especialidades.
http://congresorioja.riojasalud.es
domingo, 11 de mayo de 2008
sábado, 10 de mayo de 2008
Tutorial PET en El Mundo
Hola a todos, hoy en El Mundo digital aparece un tutorial muy interesante sobre la exploración PET-TAC
La direccion es:
http://www.elmundo.es/elmundosalud/documentos/2008/05/pet/pet.html
Salu2
Nacho Rayo
La direccion es:
http://www.elmundo.es/elmundosalud/documentos/2008/05/pet/pet.html
Salu2
Nacho Rayo
sábado, 3 de mayo de 2008
PET-CT for Radiation Oncology
Target Audience:
This course is designed for radiation oncologists, radiologists, nuclear medicine physicians, physicists, dosimetrists and others with an interest in learning the specialized skills and techniques to utilize PET/CT for radiation therapy treatment planning.
Course Overview and Learning Objectives:
This course will cover PET/CT fundamentals, application to radiation oncology treatment planning, assessment of response, surveillance, 4D CT, and 4D PET/CT for oncology imaging.
Featuring a staff of great educators including course directors:
Dwight E. Heron, MD, FACRO
Vice Chairman & Associate Professor, University of Pittsburgh School of Medicine, and Director of Radiation Services, University of Pittsburgh Cancer Institute, Pittsburgh, PA
M. Saiful Huq, PhD, FAAPM, FlnstP
Professor & Director of Medical Physics, UPMC Cancer Centers, Department of Radiation Oncology, and Professor of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Todd M. Blodgett, MD
Assistant Professor of Radiology, University of Pittsburgh School of Medicine, and Chief of Cancer Imaging, Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA
This course is designed for radiation oncologists, radiologists, nuclear medicine physicians, physicists, dosimetrists and others with an interest in learning the specialized skills and techniques to utilize PET/CT for radiation therapy treatment planning.
Course Overview and Learning Objectives:
This course will cover PET/CT fundamentals, application to radiation oncology treatment planning, assessment of response, surveillance, 4D CT, and 4D PET/CT for oncology imaging.
Featuring a staff of great educators including course directors:
Dwight E. Heron, MD, FACRO
Vice Chairman & Associate Professor, University of Pittsburgh School of Medicine, and Director of Radiation Services, University of Pittsburgh Cancer Institute, Pittsburgh, PA
M. Saiful Huq, PhD, FAAPM, FlnstP
Professor & Director of Medical Physics, UPMC Cancer Centers, Department of Radiation Oncology, and Professor of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Todd M. Blodgett, MD
Assistant Professor of Radiology, University of Pittsburgh School of Medicine, and Chief of Cancer Imaging, Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA
sábado, 12 de abril de 2008
NOPR asks CMS to expand FDG-PET coverage
Noticia referente a las últimas novedades de las indicaciones PET-TAC en Estados Unidos que han sido recientemente publicadas en el Journal of Clinical Oncology
Disponible en la web de noticias PET-TAC (www.pet-ct.blogspot.com)
Disponible en la web de noticias PET-TAC (www.pet-ct.blogspot.com)
viernes, 11 de abril de 2008
Estimados Dres,
Nos ponemos en contacto desde Grupo Geyseco (Secretaría Técnica) para anunciarles la celebración del próximo evento:I Curso de Cardioimagen: Medicina Nuclear, TC multidetector y RMque tendrá lugar en el Hospital Clinic de Barcelona los días 1-3 de Octubre de 2008.
Les adjuntamos en formato PDF el Programa Preliminar del evento. Asi mismo, pueden consultar toda la información científica del Curso en la página web:http://www.grupogeyseco.com/cardioimagen.htm
Esperando sea de su interes, aprovechamos la presente para enviarles un cordial saludo.
Atentamente,Grupo Geyseco S.L. (Secretaria Tecnica)Tel: 93 221 22 42
Nos ponemos en contacto desde Grupo Geyseco (Secretaría Técnica) para anunciarles la celebración del próximo evento:I Curso de Cardioimagen: Medicina Nuclear, TC multidetector y RMque tendrá lugar en el Hospital Clinic de Barcelona los días 1-3 de Octubre de 2008.
Les adjuntamos en formato PDF el Programa Preliminar del evento. Asi mismo, pueden consultar toda la información científica del Curso en la página web:http://www.grupogeyseco.com/cardioimagen.htm
Esperando sea de su interes, aprovechamos la presente para enviarles un cordial saludo.
Atentamente,Grupo Geyseco S.L. (Secretaria Tecnica)Tel: 93 221 22 42
miércoles, 2 de abril de 2008
Relacion cámaras por millon de habitantes
Navarra: 3,3 cámaras/millón
La Rioja: 3,3 cámaras/millón
Cantabria: 2 cámaras/millón
Valencia: 1,8 cámaras/millón
Aragón:1,6 cámaras/millón
Madrid:1,6 cámaras/millón
Andalucía:1,5 cámaras/millón
Cataluña: 1,2 cámaras/millón
Extremadura: 1 cámaras/millón
Baleares: 1 cámaras/millón
Asturias: 1 cámaras/millón
Castilla y León: 0,8 cámaras/millón
Murcia: 0,7 cámaras/millón
Galicia: 0,7 cámaras/millón
Castilla La Mancha: 0,5 cámaras/millón
País Vasco: 0,5 cámaras/millón
La Rioja: 3,3 cámaras/millón
Cantabria: 2 cámaras/millón
Valencia: 1,8 cámaras/millón
Aragón:1,6 cámaras/millón
Madrid:1,6 cámaras/millón
Andalucía:1,5 cámaras/millón
Cataluña: 1,2 cámaras/millón
Extremadura: 1 cámaras/millón
Baleares: 1 cámaras/millón
Asturias: 1 cámaras/millón
Castilla y León: 0,8 cámaras/millón
Murcia: 0,7 cámaras/millón
Galicia: 0,7 cámaras/millón
Castilla La Mancha: 0,5 cámaras/millón
País Vasco: 0,5 cámaras/millón
jueves, 27 de marzo de 2008
Asunto: [ami_mail] National Oncologic PET Registry (NOPR) Data Confirm FDG-PET Has Major Impact on Management of Cancer (AMI)
National Oncologic PET Registry (NOPR) Data Confirm FDG-PET Has Major Impact on Management of Cancer
Tuesday, 25 March 2008
Sponsored by the Academy of Molecular Imaging, NOPR Launched in May 2006
Los Angeles, Calif., Mar. 25, 2008 — Clinicians changed the intended care of more than one in three cancer patients as the result of FDG-PET scan findings, according to a study of data from the National Oncologic PET Registry, published online March 24 in the Journal of Clinical Oncology (JCO).
The study analyzed data regarding nearly 23,000 patients contributed to the NOPR by more than 1200 facilities nationwide providing positron emission tomography (PET) scans.
”The NOPR working group sought to measure the impact of PET findings on patient management in a manner minimally intrusive to care providers. This was critical for successfully collecting the large amount of data required for a robust analysis,” said Bruce Hillner, M.D., lead author for the study and professor and eminent university scholar in the Department of Internal Medicine at Virginia Commonwealth University.
Sponsored by the Academy of Molecular Imaging (AMI) and managed by the American College of Radiology (ACR) and the ACR Imaging Network (ACRIN), the NOPR was designed to collect questionnaire data from referring physicians on intended patient management before and after a FDG-PET scan.
The NOPR participating PET facility collects from referring physicians both a pre-PET questionnaire (documenting study indication, cancer type and anticipated stage, and planned management if PET were not available) and one of several post-PET questionnaires that assess the referring physician’s planned management in light of the FDG-PET findings. Analysis of data collected found that FDG-PET is associated with a 36.5% change in the decision of whether or how to treat a patient’s cancer. NOPR working group co-chair R. Edward Coleman, MD, professor of radiology and chief of the Division of Nuclear Medicine at Duke University School of Medicine and an AMI founding member, comments, “We were especially surprised by the impact of the PET findings on patients who were originally planned to have a biopsy. The procedure was avoided in approximately three-quarters of these patients.” The NOPR was launched in May 2006 in response to the Center for Medicare and Medicaid Services’ (CMS) novel “Coverage with Evidence Development” policy to collect data through a clinical registry to inform the center’s FDG-PET coverage determination decisions for currently non-covered cancer indications. Cancer types Medicare currently covers for reimbursement only through the NOPR include those of the ovary, uterus, prostate, pancreas, stomach, kidney and bladder. (For a complete list of NOPR covered cancer types and indications, go to www.cancerpetregistry.org.) Oncologist and NOPR working group co-chair, Anthony Shields, MD, professor of medicine and oncology at the Karmanos Cancer Institute at Wayne State University and chair of ACRIN’s Oncology Committee says of the research results, “These results confirm what we suspected from increasing experience with PET. However, we lacked the significant data required to prove the benefit of PET for many uncovered indications. It’s very encouraging that oncologists and other clinicians may have access to the valuable information PET affords for ensuring the best patient care.” NOPR has formally asked CMS to reconsider the current National Coverage decision on FDG-PET and to end the data collection requirements for diagnosis, staging and restaging. Medicare will review the published data and determine the next steps related to reimbursement for PET scans now only covered through the NOPR. Barry Siegel, MD, FACR, professor of radiology and chief of the Division of Nuclear Medicine at the Mallinckrodt Institute of Radiology at Washington University and chair of ACRIN’s PET Imaging Core Laboratory, also serves as an NOPR working group co-chair. "Based on these data, Medicare should strongly consider opening up the coverage to include diagnosis, staging and restaging for all cancers, states Dr Siegel.” FDG-PET, also called PET imaging or PET scan, is a test that images the function of cells to show differences between healthy tissue and diseased tissue. It uses a small amount of a radioactive chemical which is combined with sugar. This combination is called FDG, so the test is sometimes called an FDG-PET scan. It is used to evaluate various neurological and cardiac disorders, as well as for diagnosing, staging, and monitoring the treatment of many different cancers. The ACR and ACRIN worked to develop the NOPR in collaboration with registry sponsor, the Academy for Molecular Imaging since CMS announced its intent to support a PET registry in January 2005. The American Society of Clinical Oncology and the Society for Nuclear Medicine also have played key roles in guiding the project’s development.
### For more information about the NOPR please visit www.cancerpetregistry.org. For more information about positron emission tomography (PET), please visit www.radiologyinfo.org. The American College of Radiology Imaging Network (ACRIN) is a National Cancer Institute Clinical Trials Cooperative Group with operations headquartered in Philadelphia, PA and the ACRIN Biostatistics Center located at Brown University in Providence, RI. ACRIN is made up of investigators from over 100 academic and community–based medical facilities in North America and several abroad. ACRIN’s mission is to conduct clinical trials of medical imaging that will result in: 1) the earlier diagnosis of cancer,
2) allaying the concerns of those who do not have cancer, and 3 ) extending the length and improving the quality of lives of cancer patient. The ACR is a national, professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services. The Academy of Molecular Imaging is a progressive organization that builds the school of thought, scientific paradigms and clinical practices of Molecular Imaging to advance the growing field of Molecular Medicine. The Academy and its journal are involved in the various technologies of molecular imaging and multimodalities formed by merging together imaging of biological processes with imaging anatomical structures within which these processes take place. This includes such technologies as PET, optical imaging, MRI, SPECT, CT and ultrasound. The primary focus of AMI is in vivo molecular imaging, as well as in vitro studies that underlie the in vivo approaches. The Academy is comprised of four distinct components that are governed by their own councils: The Institute for Molecular Imaging Science(IMIS), the Institute for Clinical PET (ICP), the Society of Non-Invasive Imaging in Drug Development (SNIDD) and the Institute for Molecular Technologies (IMT). IMI, ICP and IMT are governed by their own councils that provide them the means to establish their own cultures and to meet their membership's needs. In addition, they will build programs and objectives involving partnerships between them. Academy of Molecular Imaging Media Contact:
Loren Kosmont310-721-9444 loren@pstrategies.net
National Oncologic PET Registry (NOPR) Data Confirm FDG-PET Has Major Impact on Management of Cancer
Tuesday, 25 March 2008
Sponsored by the Academy of Molecular Imaging, NOPR Launched in May 2006
Los Angeles, Calif., Mar. 25, 2008 — Clinicians changed the intended care of more than one in three cancer patients as the result of FDG-PET scan findings, according to a study of data from the National Oncologic PET Registry, published online March 24 in the Journal of Clinical Oncology (JCO).
The study analyzed data regarding nearly 23,000 patients contributed to the NOPR by more than 1200 facilities nationwide providing positron emission tomography (PET) scans.
”The NOPR working group sought to measure the impact of PET findings on patient management in a manner minimally intrusive to care providers. This was critical for successfully collecting the large amount of data required for a robust analysis,” said Bruce Hillner, M.D., lead author for the study and professor and eminent university scholar in the Department of Internal Medicine at Virginia Commonwealth University.
Sponsored by the Academy of Molecular Imaging (AMI) and managed by the American College of Radiology (ACR) and the ACR Imaging Network (ACRIN), the NOPR was designed to collect questionnaire data from referring physicians on intended patient management before and after a FDG-PET scan.
The NOPR participating PET facility collects from referring physicians both a pre-PET questionnaire (documenting study indication, cancer type and anticipated stage, and planned management if PET were not available) and one of several post-PET questionnaires that assess the referring physician’s planned management in light of the FDG-PET findings. Analysis of data collected found that FDG-PET is associated with a 36.5% change in the decision of whether or how to treat a patient’s cancer. NOPR working group co-chair R. Edward Coleman, MD, professor of radiology and chief of the Division of Nuclear Medicine at Duke University School of Medicine and an AMI founding member, comments, “We were especially surprised by the impact of the PET findings on patients who were originally planned to have a biopsy. The procedure was avoided in approximately three-quarters of these patients.” The NOPR was launched in May 2006 in response to the Center for Medicare and Medicaid Services’ (CMS) novel “Coverage with Evidence Development” policy to collect data through a clinical registry to inform the center’s FDG-PET coverage determination decisions for currently non-covered cancer indications. Cancer types Medicare currently covers for reimbursement only through the NOPR include those of the ovary, uterus, prostate, pancreas, stomach, kidney and bladder. (For a complete list of NOPR covered cancer types and indications, go to www.cancerpetregistry.org.) Oncologist and NOPR working group co-chair, Anthony Shields, MD, professor of medicine and oncology at the Karmanos Cancer Institute at Wayne State University and chair of ACRIN’s Oncology Committee says of the research results, “These results confirm what we suspected from increasing experience with PET. However, we lacked the significant data required to prove the benefit of PET for many uncovered indications. It’s very encouraging that oncologists and other clinicians may have access to the valuable information PET affords for ensuring the best patient care.” NOPR has formally asked CMS to reconsider the current National Coverage decision on FDG-PET and to end the data collection requirements for diagnosis, staging and restaging. Medicare will review the published data and determine the next steps related to reimbursement for PET scans now only covered through the NOPR. Barry Siegel, MD, FACR, professor of radiology and chief of the Division of Nuclear Medicine at the Mallinckrodt Institute of Radiology at Washington University and chair of ACRIN’s PET Imaging Core Laboratory, also serves as an NOPR working group co-chair. "Based on these data, Medicare should strongly consider opening up the coverage to include diagnosis, staging and restaging for all cancers, states Dr Siegel.” FDG-PET, also called PET imaging or PET scan, is a test that images the function of cells to show differences between healthy tissue and diseased tissue. It uses a small amount of a radioactive chemical which is combined with sugar. This combination is called FDG, so the test is sometimes called an FDG-PET scan. It is used to evaluate various neurological and cardiac disorders, as well as for diagnosing, staging, and monitoring the treatment of many different cancers. The ACR and ACRIN worked to develop the NOPR in collaboration with registry sponsor, the Academy for Molecular Imaging since CMS announced its intent to support a PET registry in January 2005. The American Society of Clinical Oncology and the Society for Nuclear Medicine also have played key roles in guiding the project’s development.
### For more information about the NOPR please visit www.cancerpetregistry.org. For more information about positron emission tomography (PET), please visit www.radiologyinfo.org. The American College of Radiology Imaging Network (ACRIN) is a National Cancer Institute Clinical Trials Cooperative Group with operations headquartered in Philadelphia, PA and the ACRIN Biostatistics Center located at Brown University in Providence, RI. ACRIN is made up of investigators from over 100 academic and community–based medical facilities in North America and several abroad. ACRIN’s mission is to conduct clinical trials of medical imaging that will result in: 1) the earlier diagnosis of cancer,
2) allaying the concerns of those who do not have cancer, and 3 ) extending the length and improving the quality of lives of cancer patient. The ACR is a national, professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services. The Academy of Molecular Imaging is a progressive organization that builds the school of thought, scientific paradigms and clinical practices of Molecular Imaging to advance the growing field of Molecular Medicine. The Academy and its journal are involved in the various technologies of molecular imaging and multimodalities formed by merging together imaging of biological processes with imaging anatomical structures within which these processes take place. This includes such technologies as PET, optical imaging, MRI, SPECT, CT and ultrasound. The primary focus of AMI is in vivo molecular imaging, as well as in vitro studies that underlie the in vivo approaches. The Academy is comprised of four distinct components that are governed by their own councils: The Institute for Molecular Imaging Science(IMIS), the Institute for Clinical PET (ICP), the Society of Non-Invasive Imaging in Drug Development (SNIDD) and the Institute for Molecular Technologies (IMT). IMI, ICP and IMT are governed by their own councils that provide them the means to establish their own cultures and to meet their membership's needs. In addition, they will build programs and objectives involving partnerships between them. Academy of Molecular Imaging Media Contact:
Loren Kosmont310-721-9444 loren@pstrategies.net
Suscribirse a:
Entradas (Atom)